{'52WeekChange': 0.11724138,
 'SandP52WeekChange': 0.0644362,
 'address1': '101 Hartwell Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.61,
 'askSize': 38800,
 'averageDailyVolume10Day': 13979900,
 'averageVolume': 14993417,
 'averageVolume10days': 13979900,
 'beta': 1.110364,
 'beta3Year': None,
 'bid': 1.59,
 'bidSize': 28000,
 'bookValue': -0.065,
 'category': None,
 'circulatingSupply': None,
 'city': 'Lexington',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.66,
 'dayLow': 1.52,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.124,
 'enterpriseToRevenue': 22.632,
 'enterpriseValue': 205833664,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '781-357-3080',
 'fiftyDayAverage': 1.4558572,
 'fiftyTwoWeekHigh': 3.21,
 'fiftyTwoWeekLow': 0.235,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 111876882,
 'forwardEps': -0.35,
 'forwardPE': -4.6285715,
 'fromCurrency': None,
 'fullTimeEmployees': 118,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.059439998,
 'heldPercentInstitutions': 0.09382,
 'industry': 'Diagnostics & Research',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/t2biosystems.com',
 'longBusinessSummary': 'T2 Biosystems, Inc., an in vitro diagnostics company, '
                        'develops diagnostic products and product candidates '
                        'in the United States and internationally. It provides '
                        'T2 Magnetic Resonance platform that enables detection '
                        'of pathogens, biomarkers, and other abnormalities in '
                        'various unpurified patient sample types, including '
                        'whole blood, plasma, serum, saliva, sputum, and '
                        'urine. The company also offers T2Dx, a bench-top '
                        'instrument for detecting pathogens associated with '
                        'sepsis and Lyme disease, and other applications, as '
                        'well as T2Candida panel that identifies the species '
                        'of Candida, a fungal pathogen known to cause sepsis '
                        'directly from whole blood. In addition, it is '
                        'developing Candida Auris, a multi-drug resistant '
                        'pathogen; T2Bacteria, a multiplex diagnostic panel '
                        'that detects various bacterial pathogens associated '
                        'with sepsis; and T2Lyme for the detection of various '
                        'strains of Lyme disease-causing bacteria. The company '
                        'has collaboration agreements with Canon U.S. Life '
                        'Sciences, Inc. to develop a diagnostic test panel to '
                        'detect Lyme disease; and Allergan Sales, LLC to '
                        'develop detection diagnostic test panel that adds one '
                        'additional bacteria species to the existing '
                        'T2Bacteria product candidate, as well as for testing '
                        'drug resistance directly in whole blood. T2 '
                        'Biosystems, Inc. was founded in 2006 and is '
                        'headquartered in Lexington, Massachusetts.',
 'longName': 'T2 Biosystems, Inc.',
 'market': 'us_market',
 'marketCap': 193651568,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_30844795',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -58808000,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.58,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '781-761-4646',
 'previousClose': 1.61,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 21.292091,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.66,
 'regularMarketDayLow': 1.52,
 'regularMarketOpen': 1.58,
 'regularMarketPreviousClose': 1.61,
 'regularMarketPrice': 1.58,
 'regularMarketVolume': 6844558,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 119538000,
 'sharesPercentSharesOut': 0.0581,
 'sharesShort': 6947270,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 6987176,
 'shortName': 'T2 Biosystems, Inc.',
 'shortPercentOfFloat': 0.0617,
 'shortRatio': 0.54,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'TTOO',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.14,
 'twoHundredDayAverage': 0.91834533,
 'volume': 6844558,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.t2biosystems.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02421'}